Cronos Group Inc. (CRON) Earnings Call Transcript & Summary

November 6, 2025

Toronto Stock Exchange CA Health Care Pharmaceuticals earnings 15 min

Earnings Call Speaker Segments

Operator

operator
#1

Good morning, everyone. I'm Amber, and I'll be serving as your conference operator for today. I'd like to extend a welcome to all of you as we join the Cronos Group's 2025 third-quarter earnings conference call. This call is being recorded today. Right now, I'll hand things over to Harrison Aaron, who serves as Senior Director, Investor Relations and Corporate Development. Please go ahead.

Harrison Aaron

executive
#2

Thanks, Amber. And thank you all for being here as we go through Cronos's financial and business results for the third quarter of 2025. With me today are Mike Gorenstein, our Chairman, President, and CEO, along with Anna Shlimak, our CFO. This morning Cronos put out a news release with our financial results, and it's been filed on our EDGAR and CER profiles. You'll also find this information and the prepared remarks posted on our website in the Investor Relations section. Before handing things over to Mike, I want to remind everyone that during this call we may make forward-looking statements and refer to non-GAAP financial measures. Such forward-looking statements rest on management's current expectations and assumptions, and they carry risks and uncertainties that might make actual results differ materially from what those forward-looking statements project. The factors that could make actual results differ materially from expectations are laid out in our earnings materials and in our SEC filings, which you can access on our website, and those filings qualify in their entirety any forward-looking statements we make on this call. Details on non-GAAP financial measures, including reconciliations to U.S. GAAP, are likewise available in the earnings materials posted on our website. Finally, throughout this conference call we'll be making statements about market share information, and unless we say otherwise, all market share data comes from Hifyre.

Harrison Aaron

executive
#3

We're going to give our prepared remarks at this point, and after that we'll open things up for a question-and-answer session. So with that said, I'll hand things over to the Chairman, President, and CEO of Cronos, Mike Gorenstein.

Mike Gorenstein

executive
#4

Thanks, Harrison, and good morning, everyone. In Q3 2025, Cronos Group turned in yet another record quarter, which highlights how strong our core business remains and how well our global strategy is working. Robust demand across key markets and product categories drove these results, with outstanding performance in Israel standing out in particular. We stayed focused on top-line growth, margin expansion, and disciplined cost management as we keep strengthening our operations and positioning the company for sustainable profitability. In Canada, flower supply constraints caused softer flower revenue year-over-year, but continued outperformance from our market-leading edibles and significant growth in the vape category largely offset those declines. The phase two expansion at GrowCo is now complete, and flower sales began in fall of 2025. As with any cultivation expansion, it typically takes time to dial in the new facility, and while we're on schedule and making great progress, we expect improvement over time. Overall, we believe flower sales will improve in 2026 as our supply constraints are resolved, driven by the Groco expansion and the increased supply of the high-quality flower our brands are known for. Our Spinach brand continues to be a standout performer, ending the quarter as the number two cannabis brand in Canada with 4.5% overall market share.

Mike Gorenstein

executive
#5

When it comes to flower, Spinach held the number four spot in Canada at 4.9% share, and in vapes, Spinach reached 7% share nationwide, climbing to become the number three vape brand overall. Within the vape cartridge subcategory, we captured the number two market position at 9.5% market share. Several of our vape SKUs rank among the top sellers in Canada, among them Pink Lemonade, the best-selling 1.2 g vape cartridge in Canada. On the edibles side, Spinach reinforced its category leadership, retaining the number one position at 19.7% market share. In gummies, Spinach held market leadership with 22.8% share, and four products landed in the national top 10. During Q3, SOURZ kept extending its edibles category leadership by launching fully blasted multi-packs that feature liquid diamond-infused gummies. Those multi-packs come in five of our most popular flavors, offering consumers added choice, convenience, and value when they buy Canada's number one cannabis edible. We also introduced two limited-edition seasonal offerings during the quarter, which keeps our assortment fresh and exciting for consumers. The well-liked SOURZ's Caramel Green Apple Gummy came back as a limited-time flavor, and we debuted the Sweet Green Apple 1 g vape, which features crisp, refreshing apple flavor notes that complement our edible lineup and reinforce the brand's presence in the vape category.

Mike Gorenstein

executive
#6

All of these introductions, taken together, strengthen how the brand is viewed for creating new flavors and for product excellence, while also sustaining consumer involvement and retail energy as we move toward the holiday period. Now shifting to Lord Jones: in Canada, this brand keeps raising its premium standing. Within chocolates, Lord Jones commands a 10.7% share of the market — third place in that category — and Salted Caramel Crunch Chocolate Fusions sits among the country's top 10 chocolate edibles. The brand preserved its leading spot in hash and live resin-infused pre-rolls at 17.5% share, and in August we were thrilled to introduce live resin caviar-infused pre-rolls, which further bolsters our presence in premium formats. In Israel, Cronos Group posted yet another quarter of record net revenue, with outstanding growth delivered by both the flagship Peace Naturals brand and the value-oriented Lit brand. Our offering's high quality, combined with the sales team's emphasis on pharmacy partnerships, has reinforced our leading position and our connection with patients, producing the strongest months in company history in July and August. Based on pharmacy data gathered by Cronos, Peace Naturals holds the number one spot among medical cannabis brands in Israel, supported by robust demand for flagship strains such as Wedding Cake, the market's best-selling product, and GMO, the market's second best-selling product.

Mike Gorenstein

executive
#7

During Q3, Cronos Israel kept pushing innovation forward by launching new strains, Animal and OGC, cultivated indoors within Israel as part of a fresh limited-edition product line. Another encouraging sign is that Israel's medical patient numbers have resumed growing in 2025, rising almost 5% year-to-date, after a 6% drop in patient count during 2024 that stemmed from reforms to the nation's medical cannabis program, based on data from Israel's Medical Cannabis Agency. In our remaining international markets, results came in lighter this quarter because of shipment timing, which deferred some revenue recognition into the fourth quarter. Because of that pattern, we anticipate second half 2025 net revenue from other international markets will resemble what we delivered in the first half. Germany remains the strongest performer, though we are watching possible regulatory shifts that might influence how the market develops going forward. We are pleased with the momentum in Switzerland, where Peace Naturals can now be obtained via that country's medical network. As our distribution in Australia also scales up, Peace Naturals products are now offered across seven markets: Canada, Israel, Germany, the U.K., Australia, Switzerland, and Malta. Lastly, Cronos holds one of the industry's strongest balance sheets, carrying no debt along with $824 million in cash, cash equivalents, and short-term investments, which gives us flexibility to keep investing in growth, innovation, and global expansion.

Mike Gorenstein

executive
#8

At this point, I'll hand things over to Anna, who will take you through the financial results for the third quarter.

Anna Shlimak

executive
#9

Thanks, Mike, and good morning to everyone. I'll walk through the results for our third quarter of 2025 now. Consolidated net revenue came in at $36.3 million for the company, which represents a 6% rise compared with the same period last year. That net revenue gain was fueled by stronger cannabis flower sales in Israel as well as higher cannabis extract sales in the Canadian market, partly offset by a decline in cannabis flower sales within the Canadian market. Gross profit and adjusted gross profit for the third quarter stood at $18.3 million, which works out to a 50% gross margin — a 19 percentage point gain over the 31% adjusted gross margins posted in Q3 2024. The improvement in gross margin year-over-year came from higher average sales prices, mainly because of a mix shift toward Israel, greater sales volumes, and production efficiencies, along with favorable inventory dynamics that gave Q3 2025 gross margins a boost. In light of that favorability, we'd regard the blended adjusted gross margins across Q2 and Q3 as a better indication of the underlying margins the business currently runs at. Operating expenses, leaving out restriction costs and impairments, totaled $18.6 million for the quarter, down $4.3 million year-over-year, which was driven by a $3.5 million year-over-year reduction in G&A. Adjusted EBITDA for the third quarter reached $5.7 million, an $11.7 million improvement year-over-year, powered by higher gross profit and lower operating expenses.

Anna Shlimak

executive
#10

For us, the average Adjusted EBITDA across Q2 and Q3 is a better signal of where the business's underlying profitability stands right now. Moving on to the balance sheet and cash flow statement: the company closed the quarter with $824 million in cash, cash equivalents, and short-term investments, which is down $10.2 million from Q2 2025. That decline was driven primarily by our $18.4 million convertible loan and warrant investment in High Tide, along with a $5.8 million working capital outflow, $4.6 million of CapEx spend, and $1.9 million of share repurchases, partially offset by positive cash flow from operations before changes in working capital of $19.1 million and a $1.3 million FX benefit. To sum up, our third-quarter results set records across net revenue, gross profit, and Adjusted EBITDA, showing continued improvement in our operating fundamentals as we execute against our business objectives. With that, I'd like to hand it back to Mike for a brief comment before we go into Q&A.

Mike Gorenstein

executive
#11

Thanks, Anna. In closing, what we delivered this quarter shows that Cronos's underlying business is robust and stands as proof of our strategy of products without borders. With top adult-use brands, Spinach and Lord Jones, plus traction in Israel and abroad through Peace Naturals and Lit, together with the expansion at GrowCo that we recently finished, we're set up well for ongoing growth as we head toward 2026. We have confidence in our strategy and are eager to close out 2025 on a strong note. Thank you, and we'll now take questions from the line.

Operator

operator
#12

Thank you. We're going to move into the question-and-answer portion now. Just a reminder that if you'd like to ask something, press star one one on your phone and then wait until your name is called. If you want to take your question back, just hit star one one a second time. Please hold on while we put the Q&A roster together. Bill Kirk from Roth Capital Partners has our first question. Your line is open.

Bill Kirk

analyst
#13

Morning, everyone. Mike, you brought up sales from the Groco expansion starting in the fall. Would any portion of that have landed in 3Q? On the 2026 growth discussion, could you help us frame the magnitude? For you, the capacity expansion is roughly 50%, though there were remarks about optimizing that facility over time. When you speak about growth in 2026, how much are you envisioning?

Mike Gorenstein

executive
#14

Sure. Thank you, Bill. Yeah, I think — you know, so once Groco comes online, part of that involves when sales reach us rather than going through a third party, and that was definitely toward the end. I don't believe you've actually seen much of that impact yet. That's something that will appear gradually, and I think you'll also see, as we dial it in, that magnitude will really grow into 2026. You know, working through the first cycle. The 70% capacity increase on flower is a good way to kind of think about how that can begin to affect revenue going forward, with the variables being sort of which market it gets allocated to and given the different pricing. We think it's a great growth driver along with other increases in brand launches that we have, or sorry, product launches we have in our existing markets.

Bill Kirk

analyst
#15

Great. Anna, you described the blended gross margins for 2Q and 3Q as a signal of underlying gross margins. With the new Groco capacity, would you anticipate the underlying figure to get better? Looking ahead, that's not the same as the 2Q and 3Q blend. It's a different situation, since Groco is now online.

Anna Shlimak

executive
#16

Yeah, that seems accurate. Down the road, we might see advantages from better absorption of fixed costs as that facility gets dialed in. In the near term, as we close out the year, a mix of Q2 and Q3 is indicative of the business's margins, I'd say.

Bill Kirk

analyst
#17

Great. I’ll selfishly slip in one more question. Two items, I suppose, put a bit of weight on 3Q. In Canada, you mentioned constraints on flower supply. What was the size of that effect on 3Q? And then on international, excluding Israel, there was a shift in shipment timing into 4Q. How large was that?

Mike Gorenstein

executive
#18

Thanks. Yeah, I think a lack of flower has definitely held us back. That's part of why getting Groco online has mattered so much. When you look at the overall top line, I think that's something that has certainly eased. I just want to note that I think a margin gap still exists between Canada and international. Looking ahead, costs will be, I think, somewhat improved thanks to the expansion and fixed cost absorption from Groco. More being allocated to Canada relative to international markets would drag the margin down, without factoring in the cost reductions. I still think it's all net positive. I think you should view the shipment timings as something that will normalize, so that this half will look somewhat like the first half.

Bill Kirk

analyst
#19

Great. Thanks, everyone.

Operator

operator
#20

Thanks. I see there are no more questions right now. I'd like to express my appreciation for everyone joining this conference today. That brings the program to a close, and you're free to disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cronos Group Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Cronos Group Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cronos Group Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.